Excessive Daytime Sleepiness clinical trials

Explore recruiting excessive daytime sleepiness clinical trials.

Recruiting excessive daytime sleepiness studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Excessive Daytime Sleepiness trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Long-term Extension Trial to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions.

Norway, Finland, Germany, Italy, Spain, France +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1

Czechia, Italy, France, Belgium, Spain, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2

Spain, Czechia, France, Italy, Netherlands, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia

Italy, Belgium, Czechia, France, Netherlands, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter, international, open-label, safety study of ND0612, a solution of levodopa/carbidopa delivered via a pump system as a continuous subcutaneous infusion in subjects with advanced Parkinson's Disease (BeyoND)

Italy, Austria, France, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia

Belgium, Netherlands, Czechia, Italy, France, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

Excessive Daytime Sleepiness trials by city

Excessive Daytime Sleepiness in Toronto Excessive Daytime Sleepiness in Vancouver Excessive Daytime Sleepiness in Montreal Excessive Daytime Sleepiness in Calgary Excessive Daytime Sleepiness in Edmonton Excessive Daytime Sleepiness in Ottawa Excessive Daytime Sleepiness in Winnipeg Excessive Daytime Sleepiness in Quebec City Excessive Daytime Sleepiness in Hamilton Excessive Daytime Sleepiness in Kitchener Excessive Daytime Sleepiness in London Excessive Daytime Sleepiness in Halifax Excessive Daytime Sleepiness in New York Excessive Daytime Sleepiness in Los Angeles Excessive Daytime Sleepiness in Chicago Excessive Daytime Sleepiness in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease